Isabel Lastres Becker-rekin lankidetzan egindako argitalpenak (13)

2005

  1. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice

    Brain Research, Vol. 1046, Núm. 1-2, pp. 195-206

  2. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

    Neurobiology of Disease, Vol. 19, Núm. 1-2, pp. 96-107

2004

  1. Involvement of the endocannabinoid system in motor disorders

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Núm. 3, pp. 175-182

  2. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence

    Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159

2002

  1. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

    Synapse, Vol. 44, Núm. 1, pp. 23-35

  2. Endocannabinoids and basal ganglia functionality

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 66, Núm. 2-3, pp. 257-267

  3. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease

    Neurotoxicity Research, Vol. 4, Núm. 7-8, pp. 601-608

  4. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease

    Brain Research, Vol. 929, Núm. 2, pp. 236-242

  5. The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological, and therapeutic aspects

    Pharmacology and Therapeutics, Vol. 95, Núm. 2, pp. 137-152

2001

  1. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease

    NeuroReport, Vol. 12, Núm. 10, pp. 2125-2129

  2. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors

    Journal of Medicinal Chemistry, Vol. 44, Núm. 26, pp. 4505-4508

  3. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

    European Journal of Neuroscience, Vol. 14, Núm. 11, pp. 1827-1832

1999

  1. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide

    Life Sciences, Vol. 65, Núm. 3, pp. 327-336